Scarica l'app Stockscreener
20.45
2.35%
0.47
Dopo l'orario di chiusura:
20.77
0.32
+1.56%
Precedente Chiudi:
$19.98
Aprire:
$19.55
Volume 24 ore:
3.14M
Relative Volume:
1.65
Capitalizzazione di mercato:
$2.26B
Reddito:
$12.59M
Utile/perdita netta:
$-212.39M
Rapporto P/E:
-6.6282
EPS:
-3.0853
Flusso di cassa netto:
$-185.92M
1 W Prestazione:
-4.80%
1M Prestazione:
+4.12%
6M Prestazione:
+139.18%
1 anno Prestazione:
+91.84%
Intervallo 1D:
$19.42
$20.80
Intervallo di 1 settimana:
$19.15
$21.50
Portata 52W:
$5.1501
$25.30
Immunome Inc Stock (IMNM) Company Profile
Nome
Immunome Inc
Settore
Industria
Telefono
610-321-3700
Indirizzo
18702 N. CREEK PARKWAY, BOTHELL
Confronta IMNM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
20.45 | 2.20B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-01 | Iniziato | Truist | Buy |
| 2025-09-22 | Iniziato | Goldman | Buy |
| 2025-09-05 | Iniziato | Craig Hallum | Buy |
| 2025-04-02 | Iniziato | Lake Street | Buy |
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-04-30 | Iniziato | JP Morgan | Overweight |
| 2024-04-15 | Iniziato | Guggenheim | Buy |
| 2024-01-29 | Iniziato | Leerink Partners | Outperform |
| 2023-12-19 | Iniziato | Wedbush | Outperform |
| 2021-10-29 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Immunome Inc Borsa (IMNM) Ultime notizie
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Jim Cramer on Immunome: “If You Want to Speculate on It, Fine” - Insider Monkey
Is Immunome Inc. stock supported by strong fundamentalsMarket Rumors and News & Affordable Market Investment - ulpravda.ru
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update - TechStock²
Immunome’s Stock Under the Microscope: Can IMNM Turn Recent Volatility Into a Breakout? - AD HOC NEWS
Immunome (NASDAQ:IMNM) Shares Down 7%Time to Sell? - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Decliners Report: Can Immunome Inc stock deliver strong Q4 earningsJuly 2025 Outlook & Weekly High Return Opportunities - moha.gov.vn
Immunome’s Phase 1 Cancer Study: A Potential Game-Changer? - MSN
Understanding the Setup: (IMNM) and Scalable Risk - Stock Traders Daily
Top Executive Makes Bold Move With Fresh Immunome Stock Purchase - TipRanks
Insider Buying: Clay Siegall Acquires Additional Shares of Immun - GuruFocus
Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock - MarketBeat
Immunome (IMNM) CEO Siegall buys $100k in shares By Investing.com - Investing.com Nigeria
Immunome (IMNM) CEO Siegall buys $100k in shares - Investing.com
Top Biotech Stocks To ConsiderDecember 15th - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Immunome (IMNM) - The Globe and Mail
Former CEO Of Seagen Buys Shares Of Immunome – Insider Weekends (NASDAQ:IMNM) - Seeking Alpha
Why Immunome stock surged today - MSN
Immunome (IMNM): Assessing Valuation After Strong Phase 3 Varegacestat Data and $400 Million Equity Raise - Sahm
Immunome (IMNM) price target increased by 33.44% to 34.94 - MSN
Immunome, a top 3% stock, just delivered a 'knockout' to Merck KGaA - MSN
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 383,200 Shares - MarketBeat
Guggenheim reiterates Buy rating on Immunome stock following $400M financing By Investing.com - Investing.com South Africa
Guggenheim reiterates Buy rating on Immunome stock following $400M financing - Investing.com Nigeria
Hedge Fund and Insider Trading News: Michael Hintze, Xavier Majic, Stanley Druckenmiller, Warren Buffett, Bill Ackman, Bridgewater Associates, Citadel Investment Group, Infini Capital, Immunome Inc (IMNM), White Mountains Insurance Group Ltd (WTM), a - Insider Monkey
Siegall buys Immunome (IMNM) shares worth $149k By Investing.com - Investing.com Nigeria
Immunome (NASDAQ:IMNM) Insider Purchases $204,900.00 in Stock - MarketBeat
Siegall buys Immunome (IMNM) shares worth $149k - Investing.com India
Tsai Philip buys $204,899 in Immunome stock By Investing.com - Investing.com South Africa
Tsai Philip buys $204,899 in Immunome stock - Investing.com
Immunome CTO Philip Tsai Buys 10,000 Shares - TradingView — Track All Markets
Will Immunome Inc. stock see insider buyingMarket Growth Summary & Verified Swing Trading Watchlist - Улправда
Clay Siegall Bought 5.8% More Shares In Immunome - simplywall.st
Immunome Chairman Acquires 5.8% More Stock - Yahoo Finance
Aug Breakouts: Will Immunome Inc. stock see insider buyingWeekly Profit Report & Free AI Powered Buy and Sell Recommendations - Улправда
How institutional buying supports Immunome Inc. stock2025 Biggest Moves & Fast Moving Stock Trade Plans - ulpravda.ru
Immunome Inc. Stock (IMNM) Opinions on Phase 3 RINGSIDE Trial Results - Quiver Quantitative
Immunome Inc Azioni (IMNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):